2010
DOI: 10.1016/j.hrtlng.2009.10.005
|View full text |Cite
|
Sign up to set email alerts
|

Plasma circulatory markers in male and female patients with coronary artery disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
14
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 36 publications
(16 citation statements)
references
References 36 publications
2
14
0
Order By: Relevance
“…This is especially evident because levels of IL-2, IL-6, IL-10, IL-18, TNF-a, IFN-c, ET-1, sICAM-1 and sVCAM-1 were significantly higher in the case group than in the control group (Table 4). This finding is consistent with Jha et al's [22] observation that inflammatory cytokines might take part in the development of atherosclerosis and trigger the occurrence of AMI. It is of particular note that C-reactive protein (CRP) is an extremely important indicator of atherosclerosis due to its diagnostic and predictive capabilities (Table 3).…”
Section: Discussionsupporting
confidence: 93%
“…This is especially evident because levels of IL-2, IL-6, IL-10, IL-18, TNF-a, IFN-c, ET-1, sICAM-1 and sVCAM-1 were significantly higher in the case group than in the control group (Table 4). This finding is consistent with Jha et al's [22] observation that inflammatory cytokines might take part in the development of atherosclerosis and trigger the occurrence of AMI. It is of particular note that C-reactive protein (CRP) is an extremely important indicator of atherosclerosis due to its diagnostic and predictive capabilities (Table 3).…”
Section: Discussionsupporting
confidence: 93%
“…The reason why we saw an increase in hsCRP in both groups is unclear, but it may be related to the large number of smokers in both groups (68.3% in A and 61.7% in S group) because a higher level of hsCRP is described in smokers with CAD. 32 The level of hsCRP did not correlate with plaque volume or plaque composition, and a similar finding was reported by Park et al 33 All other markers decreased during the present study, but differences between groups and differences between baseline and follow-up were not significant.…”
Section: Secondary Endpoint: Changes In Lipids and Pro-inflammatory Csupporting
confidence: 91%
“…VCAM-1 can also be released from the endothelial surface through cleavage by a disintegrin and metalloprotease 17 (ADAM17) (97) and, although less characterized, may be released by ADAM8 (185,186) or ADAM9 (103,222). Therefore, VCAM-1 is present in the plasma in a soluble form (sVCAM-1) and is used as predictive biomarker of disease (17,127,154,297,319). Levels of sVCAM-1 in plasma increase with activation of the endothelium in multiple diseases (44,55,89,98,133,154,206,219,227).…”
Section: Vcam-1 Regulation Of Leukocyte Recruitment and Inflammatmentioning
confidence: 99%